A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Dr. Sevigny joins Rapport following his tenure as chief medical officer at Prevail Therapeutics See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze ...

Dr. Sevigny is a physician-scientist with more than 15 years of leadership in translational and clinical drug development, including as chief medical officer at Prevail Therapeutics, a wholly ...

Dr. Sevigny is a physician-scientist with more than 15 years of leadership in translational and clinical drug development, including as chief medical officer at Prevail Therapeutics, a wholly owned ...

the company also have active partnerships with Novartis AG (NVS), Caribou Biosciences (CRBU), and Prevail Therapeutics. However, given that, to date, Precision has not announced major changes in ...

Thank you for standing by, and welcome to Corcept Therapeutics conference call ... The matter of the absolute schedule, if we prevail, Teva would lose FDA approval of its product and be required ...

Learn about the vital functions of the lymphatic system, early warning signs of lymphatic disorders, and effective treatment options available.

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

Federal Circuit Ruling Potentially Upends Orange Book Patent Listing Requirements, Expert Analysis Reveals This ruling marks a pivotal moment in Hatch-Waxman practice, potentially altering how ...

Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the ...